Extent of data breaches in pharmaceutical sector revealed
3 September 2015 | By Victoria White
The extent of data breaches in the pharmaceutical sector has been revealed by a survey that shows 60% have lost important data...
List view / Grid view
News
PHE calls for pregnant woman to have whooping cough vaccine
3 September 2015 | By Victoria White
PHE is calling for pregnant women to take up the whooping cough vaccine as surveillance figures confirm that whooping cough activity remains at raised levels in England...
NICE says ‘no’ to apremilast for psoriatic arthritis
3 September 2015 | By Victoria White
NICE has published final draft guidance which does not recommend apremilast, saying that there is not enough evidence to demonstrate apremilast slows progression of psoriatic arthritis...
Amgen submits MAA for etelcalcetide to the EMA
3 September 2015 | By Victoria White
If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously for the treatment of SHPT in patients with chronic kidney disease...
UCB to sell Kremers Urban to Lannett
3 September 2015 | By Victoria White
Lannett Company has entered into a definitive agreement to acquire UCB’s US generics subsidiary, Kremers Urban Pharmaceuticals, for $1.23 billion...
FDA grants Fast Track designation to iclaprim
3 September 2015 | By Victoria White
The FDA has granted Fast Track designation to iclaprim to treat acute bacterial skin and skin structure infections and hospital acquired bacterial pneumonia...
FDA approves label update for Teflaro
2 September 2015 | By Victoria White
Teflaro is now approved for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia...
Abbott announces positive results of its naturally dissolving stent
2 September 2015 | By Victoria White
ABSORB Japan, a trial comparing the safety and effectiveness of Abbott's fully dissolving Absorb heart stent to Xience, has produced positive results...
Positive Phase III results demonstrate efficacy of Avycaz
2 September 2015 | By Victoria White
Positive results from RECAPTURE 1 and 2, Phase III studies evaluating the antibiotic Avycaz as a treatment for patients with cUTI, have been announced...
FDA accepts supplemental Biological License Application for Opdivo
2 September 2015 | By Victoria White
The FDA has accepted for filing and review the supplemental Biological licence Application for Opdivo for the treatment of patients with non-squamous NSCLC...
Coulter Partners announces further expansion of Nordics team
2 September 2015 | By Coulter Partners
Global Life Sciences search specialist, Coulter Partners is pleased to announce the appointments of Nicolaj Moerk Thomsen as Senior Consultant and Lisbeth Holm as Research Associate in their new Copenhagen offices...
Allergan acquires Naurex; strengthens mental health pipeline
2 September 2015 | By Victoria White
Allergan has completed the acquisition of Naurex, a biopharmaceutical company developing therapies for challenging disorders of the central nervous system...
Heart failure medicine LCZ696 to be available to the NHS
2 September 2015 | By Victoria White
Heart failure treatment LCZ696 (sacubitril valsartan) has been given a positive scientific opinion under the MHRA Early Access to Medicines Scheme...
NICE draft guidance conditionally recommends Vimizim
2 September 2015 | By Victoria White
NICE has provisionally recommended BioMarin’s Vimizim for the treatment of the very rare inherited lysosomal storage disease, mucopolysaccharidosis type IVa...
BMS gets exclusive rights to acquire Promedior
2 September 2015 | By Victoria White
As well as granting exclusive rights to acquire Promedior, the agreement grants Bristol-Myers Squibb worldwide rights to Promedior's lead asset PRM-151.
